Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic Complication Clear all
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

NCT03547453
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Not applicable Interventional

Permissive Intrapartum Glucose Control

NCT05553275
View directory record Official record
Conditions
Gestational Diabetes, Pregestational Diabetes
Interventions
Usual Care, Permissive intrapartum glucose control
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 4 Interventional

Effect of Sulodexide in Overt Diabetic Nephropathy

NCT00130312
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
View directory record Official record
Conditions
Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions
Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Not listed Not applicable Interventional

Sensor-based Balance Training in Diabetes: A Virtual Reality Paradigm

NCT02214329
View directory record Official record
Conditions
Diabetes
Interventions
Sensor-based exercise training, In-home balance training
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

NCT01439854
View directory record Official record
Conditions
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 4 Interventional

Arterial pH and Total Body Nitrogen Balances in APD

NCT00586131
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 20, 2026, 11:45 PM EDT
Completed No phase listed Observational

Long Term Follow-Up of Diabetic Retinopathy

NCT00001395
View directory record Official record
Conditions
Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy, Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 11:45 PM EDT
Withdrawn Not applicable Interventional

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

NCT03404895
View directory record Official record
Conditions
Diabetes, Diabetic Foot Ulcer, Edema
Interventions
Conventional Therapy, Venous Stent(s)
Device
Lead sponsor
Windsor Ting
Other
Eligibility
30 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Withdrawn Phase 1 Interventional

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

NCT06138327
View directory record Official record
Conditions
Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions
BMN 255, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 20, 2026, 11:45 PM EDT
Completed No phase listed Observational

Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population

NCT03482154
View directory record Official record
Conditions
Stem Cell Transplant Complications, Hyperglycemia, Hypoglycemia
Interventions
Hematopoietic Stem Cell Transplant
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 30 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Not applicable Interventional Results available

Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy

NCT00654641
View directory record Official record
Conditions
Surgical Wound Dehiscence, Wound Infection
Interventions
Negative pressure wound closure, Standard wound closure
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Charleston, West Virginia • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
vildagliptin, sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 20, 2026, 11:45 PM EDT
Withdrawn Phase 4 Interventional

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144
View directory record Official record
Conditions
Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Interventions
Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
View directory record Official record
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting No phase listed Observational

Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study

NCT02841553
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
0 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

NCT05909046
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions
Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Not yet recruiting No phase listed Observational

Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness

NCT07356986
View directory record Official record
Conditions
Gestational Diabetes, Postpartum
Interventions
Dexcom Stelo real-time Continuous Glucose Monitor
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Santa Barbara, California • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

NCT06106295
View directory record Official record
Conditions
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions
Metyrapone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 20, 2026, 11:45 PM EDT
Completed No phase listed Observational

Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients

NCT05086185
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Kalemic Response to Orange Juice, Kalemic Response to Orange Juice with Fiber
Diagnostic Test · Dietary Supplement
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 20, 2026, 11:45 PM EDT